AC Nova Technologies Inc Announces Health Canada Approval of NutraPause
NutraPause is a botanical supplement clinically shown to relieve vasomotor symptoms (hot flashes and night sweats) associated with perimenopause and menopause.
Toronto, Canada (PRWEB) November 19, 2013
AC Nova Technologies Inc (aka ATI Pharma), a leader in the development of evidence-based botanical supplements, is pleased to announce that Health Canada has approved NutraPause for the treatment of vasomotor symptoms associated with perimenopause and menopause (NPH 80031417).
ATI Pharma anticipates that NutraPause will be available in Canada and the USA in the early First Quarter of 2014.
There are approximately 33 million women in the United States and in Canada between the ages of 45-59, and the average age of menopause in the U.S and Canada is 51. Based on survey data, an estimated 50% of postmenopausal women experience vasomotor symptoms.
Traditional Hormone Replacement Therapy (HRT) was the main treatment for menopause for decades. In 2002 findings from a large clinical study called the Women`s Health Study Initiative (WHI) that included 27,000 women raised concerns about the long term safety of HRT (1,2). This has led to a search for therapies that do not increase the risk of heart attacks, strokes, blood clots or breast cancers.
The approval of NutraPause is an important, novel, effective and safe alternative therapy to traditional hormone therapies for alleviating those vasomotor symptoms often associated with perimenopause and or menopause. According to Ms. Carmella Angus (Founder and Chairman of the Board of ATI Pharma), “NutraPause presents a new opportunity for women and their doctors and/or other healthcare practitioners to discuss alternative effective and safe treatment options for managing hot flashes and night sweats.”
About NutraPause and Its Clinical Program
NutraPause is manufactured using a patented methodology developed by Scientists at the University of Singapore (NUS). This patented platform technology has shown that one of the active ingredients in NutraPause is able to modulate the estrogen and androgen receptors in vitro and in vivo (4).
NutraPause`s active ingredients have been demonstrated through a Phase III clinical trial (3) to be effective and safe in alleviating symptoms often associated with perimenopause and menopause.
A double-blind placebo controlled clinical study using the same active ingredients and dosage approved for NutraPause (3) showed a significant decrease in the weekly number of vasomotor symptoms (hot flashes and night sweats) compared to baseline after 12 weeks of treatment of 46% (p=0.0011). The study also showed a decrease in symptom severity. At the end of the study the number of vasomotor symptoms was decreased in half in 43% of the women receiving NutraPause compared to placebo with 6%. Safety data suggests that these active ingredients are well tolerated with no significant adverse events in the treatment group versus placebo (3).
According Ms. Angus, “This clinical study may be the first to have shown clinically significant efficacy in reducing vasomotor symptoms using alternative herbal therapy.”
Indications Approved by Health Canada (NPH 80031417)
Adult Females: Take 1-2 capsules 2 times per day. Take after food, twice per day (morning and evening) or as directed by a healthcare practitioner.
Recommended Use: Botanical supplement that supports the management of symptoms and discomfort commonly associated with perimenopause or menopause. A healthy combination of botanical extracts derived from Eucommia Ulmoides and Mung Bean. Clinically shown to relieve hot flashes or nights sweats in women experiencing at least 3 hot flashes or night sweats per day. The combination of Eucommia Ulmoides and Mung Bean extract used in NutraPause has been shown in a controlled clinical study to significantly reduce the number/frequency of hot flashes and night sweats (vasomotor symptoms).
Cautions and Warnings: As with all nutritional supplements, if you are suffering from a medical condition, please consult your healthcare professional before use.
Contra-Indications: Women pregnant or lactating
Menopause is a normal, natural event. It marks the permanent end of fertility and is usually confirmed when a woman has not menstruated for 12 consecutive months. For American women this typically happens at between ages of 48 and 52 and sometimes it occurs before the age of 40 but when that happens it is referred to as “premature menopause”. Menopause is preceded by several years of a transition period referred to as the perimenopausal phase which often lasts about 4 years. Although menopausal symptoms may vary amongst women, many of these symptoms are often very disruptive to a women`s quality of life.
Menopause is associated with reduced functioning of the ovaries due to aging, resulting in lower levels of estrogens and other hormones such as testosterone. Changes in these hormones cause many symptoms of menopause, which may include hot flashes and night sweats. While menopause is natural, many women suffer for years with symptoms that also disrupt their sleep but at the same time they have not discussed treatment options for their symptoms with their doctor and or health care practitioner.
About AC Nova Technologies Inc (aka ÀTI Pharma`)
AC Nova Technologies Inc (aka ATI Pharma) is headquartered in Canada with the USA affiliate in Denver Colorado. AC Nova Technologies is the exclusive licensee of NUS’s patented platform technology. At ATI Pharma, we strive to bring to the public only evidence-based natural therapies that have been clinically shown to improve quality of life and/or delay the onset of a medical condition. We strive to set the standard for quality, safety and value in the licensing, development and manufacture of health care products. To learn more, please visit us at http://www.atipharma.com or contact us directly.
Distributor of NutraPause (Canada)
AC Nova Technologies is also pleased to announce that it has signed an exclusive distribution agreement with a well-established distributor in Canada.
Contact for Health Products and Pharmacy Chains in Canada
TFB & Associates Limited (Distributor for Canada Only)
Mr. Bob Riddell
President, TFB &Associates Limited
905-940-0889 Ext 224
Contact for Health Products and Pharmacy Chains in the USA
Keith Larson (USA)
President and Co-Founder, AC Nova Technologies Inc
Contact for Investors
Keith Larson (USA)
President, AC Nova Technologies Inc.
Contact for Canada, Europe and/or Asia
Carmella Angus MSc. MBA
Founder and Chairperson of the Board of Directors (North America)
DISCLOSURE NOTICE: The information contained in this release is as of November 4th, 2013. ATI Pharma assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information that involves uncertainties about NutraPause. Such uncertainties may include, among other things, the uncertainty regarding the precise date NutraPause will be available in the U.S and the uncertainty regarding the commercial success of NutraPause in the U.S.
ATTENTION: ATI Pharma’s Brand Name NutraPause is not to be confused with such names as “Natura Pause” OR “Nutri Pause” which are entirely different products.
1. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy menopausal women. principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333
2. The Women's Health Initiative Steering Committee. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. The Women’s Health Initiative Randomized Controlled Trial. JAMA 2004; 291: 1701-1712.
3. Garcia et al., (2010) Use of a multibotanical (aka Nutrapause) for the relief of menopausal vasomotor symptoms: a double blind placebo controlled study. Journal of North American Menopause Society Vol 17 No 2 pg 303-308
4. Ong C Y PhD and Yong L MD (2005) Method for Modulating Steroidogenic Activity National University of Singapore United States Patent 6,095,714,B2
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/11/prweb11343246.htm